Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world prophylaxis with SCT800 in moderate and severe hemophilia A in China
ChiCTR2100052152Phase 4Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of omfiloctocog alfa in hemophilia A, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Annualized bleeding rate and Annualized joint bleeding rate. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
omfiloctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on ChiCTR2100052152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052152.